Perspectives

Current challenges in CLL treatment 2:52
Current challenges in CLL treatment
Brian Koffman • 9 Sep 2021
Patient segmentation for targeted therapy in myeloma 4:52
Patient segmentation for targeted therapy in myeloma
Faith Davies et al. • 11 Sep 2021
Precursor conditions: management of smoldering myeloma 6:05
Precursor conditions: management of smoldering myeloma
Irene Ghobrial et al. • 10 Sep 2021
Long-term disease-free survival in myeloma 1:59
Long-term disease-free survival in myeloma
Heinz Ludwig et al. • 9 Sep 2021
The new era of myeloma therapies 2:30
The new era of myeloma therapies
Irene Ghobrial et al. • 10 Sep 2021
Women in myeloma 2:01
Women in myeloma
Irene Ghobrial et al. • 10 Sep 2021
The evolution of MRD for myeloma 3:15
The evolution of MRD for myeloma
Lanny Kirsch • 9 Sep 2021
MRD in myeloma: the patient perspective 2:49
MRD in myeloma: the patient perspective
Lanny Kirsch • 9 Sep 2021
MRD’s place in decision making 1:26
MRD’s place in decision making
Lanny Kirsch • 9 Sep 2021
BiTE and CAR-T combinations for myeloma 2:01
BiTE and CAR-T combinations for myeloma
Noopur Raje • 11 Sep 2021
IMW 2021: MRD highlights 2:50
IMW 2021: MRD highlights
Daniel Auclair • 11 Sep 2021
MRD: from clinical trials to clinical practice 1:43
MRD: from clinical trials to clinical practice
Katja Weisel • 10 Sep 2021
MRD: its role and importance for myeloma treatment 1:41
MRD: its role and importance for myeloma treatment
Katja Weisel • 10 Sep 2021
Sequencing BCMA-targeted therapies in myeloma 1:29
Sequencing BCMA-targeted therapies in myeloma
Niels van de Donk • 10 Sep 2021
The management of R/R multiple myeloma patients 6:58
The management of R/R multiple myeloma patients
Meral Beksac • 10 Sep 2021
COVID-19 in myeloma: what have we learnt? 5:53
COVID-19 in myeloma: what have we learnt?
Joaquin Martinez-Lopez • 10 Sep 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals